SCHEMBL5566935

SCHEMBL5566935

C=C(C(=O)c1ccc(S(=O)(=O)N2CCCCC2C(=O)O)cc1)c1cc(-c2cccs2)c(OC)cc1OC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 3/20 0.48
ALDH1A1 P00352 3/20 0.48
KMT2A Q03164 5/20 0.43
USP2 O75604 4/20 0.43
TDP1 Q9NUW8 3/20 0.43
MEN1 O00255 3/20 0.43
KDM4E B2RXH2 2/20 0.43
TP53 P04637 2/20 0.43
ALOX15 P16050 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
TSHR P16473 2/20 0.43
LMNA P02545 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 3/20 0.40
HSD17B10 Q99714 1/20 0.40
FKBP1A P62942 3/20 0.39
MMP1 P03956 1/20 0.39
MMP3 P08254 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5566937 0.82 TNFRSF1A (0.52) HTTALDH1A1KMT2AUSP2TDP1
SCHEMBL5566939 0.82 TNFRSF1A (0.52) HTTALDH1A1KMT2AUSP2TDP1
SCHEMBL5564501 0.80 RXFP1 (0.39) ALDH1A1KMT2AUSP2MEN1KDM4E
SCHEMBL6879563 0.79 TNFRSF1A (0.41) HTTALDH1A1KMT2AUSP2MEN1
SCHEMBL4727715 0.78 TNFRSF1A (0.44) ALDH1A1KMT2AMEN1KDM4ELMNA
SCHEMBL5560851 0.76 L3MBTL1 (0.39) ALDH1A1KMT2ATDP1MEN1KDM4E
SCHEMBL5560061 0.75 TNFRSF1A (0.41) ALDH1A1KMT2AMEN1KDM4EL3MBTL1
SCHEMBL5566988 0.73 KMT2A (0.51) HTTALDH1A1KMT2ATDP1MEN1
SCHEMBL6040670 0.73 TNFRSF1A (0.49) ALDH1A1KMT2AMEN1KDM4EL3MBTL1
SCHEMBL6040890 0.73 TNFRSF1A (0.39) ALDH1A1KMT2AMEN1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US claimed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US claimed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US claimed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO claimed
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US disclosed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 HTT 357/4885ALDH1A1 1653/4885KMT2A 3609/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 HTT 357/4885ALDH1A1 1653/4885KMT2A 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.